Transitional cell carcinoma laboratory findings
|
Transitional cell carcinoma Microchapters |
|
Differentiating Transitional cell carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Transitional cell carcinoma laboratory findings On the Web |
|
American Roentgen Ray Society Images of Transitional cell carcinoma laboratory findings |
|
Directions to Hospitals Treating Transitional cell carcinoma |
|
Risk calculators and risk factors for Transitional cell carcinoma laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Suveenkrishna Pothuru, M.B,B.S. [2] Anum Gull M.B.B.S.[3]
Overview
Laboratory findings consistent with the diagnosis of transitional cell carcinoma include blood in the urine, abnormal cells in the urine, and elevated tumor markers.
Laboratory Findings
- Blood in the urine ( Gross/Microscopic)
- Abnormal cells in the urine
- Tumor marker tests: Urine biomarkers could have a significant role in determining which individuals require cystoscopy, as well as determining those who might need evaluation of the upper urinary tract.
- Bladder tumor–associated antigen (BTA)[2]
- Nuclear matrix proteins 22 (NMP)[3]
- NMP52[4]
- Mucin and carcinoembryonic antigen (CEA)
- Hyaluronic acid
- Bladder cancer associated NMP 4 (BLCA-4)
- Survivin
- Cytokeratin (CK) 8 and CK 18
- Low red blood cell count
- Elevated alkaline phosphatase
- UroVysion test is a multicolor FISH assay using probes that can detect aneuploidy of chromosomes 3, 7, or 17 or loss of the 9p21 locus
References
- ↑ Bladder Cancer. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/bladder/diagnosis/?region=ab#urinetest Accessed on October, 6 2015
- ↑ Guo A, Wang X, Gao L, Shi J, Sun C, Wan Z (2014). "Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: A meta-analysis". Can Urol Assoc J. 8 (5–6): E347–52. doi:10.5489/cuaj.1668. PMC 4039599. PMID 24940462.
- ↑ Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y; et al. (2005). "Detection of bladder cancer using a point-of-care proteomic assay". JAMA. 293 (7): 810–6. doi:10.1001/jama.293.7.810. PMID 15713770.
- ↑ Attallah AM, Sakr HA, Ismail H, Abdel-Hady el-SK, El-Dosoky I (2005). "An office-based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer". BJU Int. 96 (3): 334–9. doi:10.1111/j.1464-410X.2005.05627.x. PMID 16042726.